Vol. 6 No. 6 (2026): June
Reimbursement Reviews

Durvalumab (Imfinzi)

decorative image of the issue cover

Published June 23, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses durvalumab (Imfinzi), 50 mg/mL, concentrate for IV infusion.
  • Indication: Durvalumab in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (stages II to IVa).